



THE MOST RESEARCHED NON-INVASIVE LASERS IN THE WORLD.



Pg. 4 - GVL NEW RELEASE!

405nm & 520nm lasers combined!

Pg. 5 - XLR8

Dual Red - Perfect Entry Level Laser!

Pg. 6 - EVRL

Dual Red/Violet - Most Popular Laser!

Pg. 7 - Base Station

Deluxe edition charging base with (3) touchscreen hand-held devices.

Pg. 9 - FX 635

Triple Red - Unattended laser scanner.

Pg. 10 - FX 405

Newest rendition of the FX 635 with a red/violet laser combo.

Pg. 13 - Zerona

The most advanced advanced failoss laser FDA cleared for overall body circumference reduction.

Pg. 14-15 -FDA Clearances & Return on Investment

Pg. 17 - Support & Benefits

Did you know

Erchonia is the World Leader in Low Level Laser technologies and every laser Erchonia manufactures has gone through the most rigorous clinical trial standards possible to prove the safety and effectiveness of our products.

Leaders in Research

For over two decades, Erchonia has been committed to the research of low level laser therapy (LLLT) through extensive clinical studies and has attained more than **(22) FDA indications for use.** Erchonia made history in 2002 when the FDA granted Erchonia market clearance for the first non-thermal laser in history. This created a new category for the FDA called NHN Laser, making Erchonia the gold standard for low level laser technology.

Contents



ABOUT US

(888) 242-0571 www.erchonia.com

Founded in 1996, Erchonia Corporation stands as a global leader in the field of low-level laser technology (LLLT). With a relentless dedication to research and development, Erchonia has consistently pioneered new advancements in the application of LLLT for a variety of medical purposes, ranging from pain management to wound healing. The corporation's unwavering commitment to clinical research has resulted in (22) FDA clearances, underscoring their position at the forefront of non-invasive laser innovations. Beyond its product offerings, Erchonia is also recognized for its educational initiatives, providing professionals with the necessary training to integrate laser therapy into their practices effectively. With an international footprint and a vision to continue advancing the boundaries of laser medicine, Erchonia Corporation remains a beacon of innovation in the medical technology sector. To ensure a steadfast adherence to our unique allencompassing approach, our company serves as manufacturer, marketer, developer, promoter, creator and user of all our products.

1

Fundamentals of Photochemistry

The process of low-level laser therapy is based on a photochemical reaction in which discrete bundles of energy called photons are absorbed within the visible light spectrum of 380–700nm. The photon induced chemistry ultimately gives rise to the observable effect at the biological level. In order to achieve maximum photobiological effects, Erchonia adheres to the following delivery fundamentals:

- Laser light that is monochromatic and coherent having only one wavelength. Light from LEDs (Light Emitting Diodes) cannot achieve the same narrow band of wavelength, instead LEDs produce light that is disorganized or incoherent. Laser light is dramatically more effective in producing photochemical effects than LED. This is evident in over a dozen, double-blind, placebo controlled clinical trials using Erchonia lasers where test subjects established both statistical significance and clinically meaningful results over the placebo group which received LED treatment.
- Laser output under 500mw. Devices with a laser output above 500mw are not LLLT (Low-Level Laser Therapy). Instead, they are classified as High Intensity Laser (HIL) or Class 4 Lasers. These devices are FDA cleared under the ILY product code which started as a heating pad and has expanded to thermal lasers that are intended to "provide topical heating for the purpose of elevating tissue temperature for temporary relief of muscle and joint pain and stiffness, arthritis pain, or muscle spasm, the temporary increase in local blood circulation and/or promoting relaxation of muscle". The FDA has now made the ILY products 510(k) FDA exempt based on the device requirements of raising skin temperature to 40-45°C. LLLT is a non-thermal process and classified under FDA product code called NHN, powered light-based laser non thermal instrument with non-heating effect for adjunctive use in pain therapy. Blinded and controlled trials are required for new 510(k) indications.

"LLLT delivered at low doses tends to work better than the same wavelength delivered at high levels, which illustrates the basic concept of biphasic dose response or hormesis" (Calabrese 2001b)

• Lasers within the visible light spectrum of 380-700nm. The primary mechanism for the absorption of visible light photons is the elevation of electrons to higher energy levels through photochemistry. Another type of electromagnetic radiation is infrared (IR) which includes wavelengths higher than 700nm. The infrared light spectrum exhibits strong absorption from vibrations of the water molecule. The result of infrared absorption is heating of the tissue since it increases molecular vibrational activity Simply, while visible light can produce photochemical effects, infrared only produces molecular rotations and vibrations.

Benefits of Visible Light Therapy

The Mitochondria Electron Transport (ETC).

Four of the five protein complexes make up the "respiratory chain" and are involved in the transfer of electrons, which at three points is coupled with the translocation of protons across the inner mitochondrial membrane. The resulting proton gradient is used by the ATP synthase complex (the fifth enzyme complex) to phosphorylate ADP. The electron transport chain of mitochondria described, especially their use in a complex, makes it possible to significantly detail the understanding of the pathogenesis of disorders of cell energy exchange that occurs in various diseases, which will improve the prevention and correction of mitochondrial dysfunction.

Complex 1:

Complex I, or NADH dehydrogenase, is the main entry point for electrons into the respiratory chain. Complex I plays a central role in cellular respiration and oxidative phosphorylation, providing up to 40% of the proton gradient for ATP synthesis.

Complex 2:

Complex II, or succinate dehydrogenase, is another entry point for electrons into the respiratory chain, it is not associated with the translocation of protons across the membrane, transfers electrons from succinate to ubiquinone, and directly binds the Krebs cycle with the respiratory chain.

Complex 3:

The central component of the OxPhoS system is cytochrome c-reductase, or complex III, which functions as a dimer. It transports electrons from reduced ubiquinone (ubiquinol) to cytochrome c, a small mobile electron carrier bound to the outer surface of the inner membrane. This multi-protein transmembrane complex is encoded by the mitochondrial (cytochrome b) and nuclear genomes. Electronic transport in complex III is associated with the transfer of protons from the matrix to the intermembrane space. Thus, cytochrome c in the electron transport chain of mitochondria acts as an electron acceptor for complex III (cytochrome c reductase) and an electron donor for complex IV (cytochrome oxidase)

Complex 4:

Complex IV is the terminal oxidase of the aerobic respiratory electron transport chain, which catalyzes the transfer of electrons from cytochrome c to oxygen to form water. Complex IV sequentially oxidizes four cytochrome c molecules and, accepting four electrons, reduces O2 to H2O. During O2 reduction, four H+ are captured from the mitochondrial matrix to form two H2O molecules, and four more H+ are actively pumped across the membrane. Thus, cytochrome oxidase contributes to the creation of a proton gradient for ATP synthesis and is part of the oxidative phosphorylation pathway



The Newest Addition to Cold Laser Therapy & The World's Most Energetic Laser.

The GVL was shown to be the most effective wavelength combination for the increase of ROM and decrease in pain in a single session. This is currently the first and only green wavelength laser FDA cleared for pain and inflammation. Unique to the green wavelength is the ability to affect complex 3 in the Electron Transport Chain (ETC). No other wavelength can impact this complex, and it is critical for moving to complex 4 to produce ATP.

Shown to stimulate complex 1, 2 & 3.

Payments as low as \$410 per month.

*Price may vary, does does not include tax & shipping.

Specifications

- Configuration: (2) 7.5 mW Line Generated Laser Diodes with Patented Optics
- Wavelength: 520nm & 405nm
- Modulation: Constant Wave (CW) & Pulsed (Hz)
- 100 User Defined Memory Channels
- 1 Preset Protocol Channel
- Display: Full Color TFT Touchscreen Technology
- Power Source: 3.7 VDC Lithium-ion Polymer Battery
- Enclosure: Machined Billet Aluminum
- · Weight: Less Than 1lb. (.30 kgs) (Device Only)
- · Accessories: Power Cord, Wireless Charging Base, and Safety Glasses
- Compliant to: ISO 13485 Medical Device Quality, IEC 60601-1, 60601-1-2, IEC 60825-1, CB Certified, CE Mark, CMDCAS
- Laser Class 2 / Device Class II (USA); 2a (EU)

ORDER # GVL



The revolutionary XLR8 handheld laser device. This dual-diode laser featuring dual red 640nm lasers as been the work horse of Erchonia doctors for 25 years. Proven the efficacy of laser therapy and the amazing benefits you will bring to your practice.

This is our most popular entry level laser — New to laser therapy? Then XLR8 is the laser for you!

Shown to stimulate complex 4.

Payments as low as \$194 per month.

*Price may vary, does does not include tax & shipping.

Specifications

- Configuration: (2) 7.5 mW Line Generated Laser
 Diodes with Patented Optics
- Wavelength: 640nm
- Modulation: Constant Wave (CW) & Pulsed (Hz)
- 100 User Defined Memory Channels
- 7 Preset Protocol Channels
- Display: Full Color TFT Touchscreen Technology
- Power Source: 3.7 VDC Lithium-ion Polymer Battery
- Enclosure: Machined Billet Aluminum
- Weight: Less Than 1lb. (.30 kgs) (Device Only)
- · Accessories: Power Cord, Wireless Charging Base, and Safety Glasses
- Compliant to: ISO 13485 Medical Device Quality, IEC 60601-1, 60601-1-2, IEC 60825-1, CB Certified, CE Mark, CMDCAS
- Laser Class 2 / Device Class II (USA); 2a (EU)

ORDER # XLR8



The EVRL, since its release, has become our most popular handheld device by offering the versatility of a red and violet wavelength taking outcomes to a whole new level. By combining these two specific wavelengths into one treatment modality, patients received better results during clinical studies than using just 635nm alone. Experience the freedom of this incredible new technology – Improving health and wellness has never been easier.

Shown to Stimulate Complex 1,2 & 4

Payments as low as \$311 per month.

*Price may vary, does does not include tax & shipping.

Specifications

- Configuration: (1) 7.5mW Line Generated Red Laser Diode, (1) 7.5m Line Generated Violet Laser Diode with Patented Optics
- Wavelength: 640nm & 405nm
- 1 Preset Protocol Channel
- Modulation: Constant Wave (CW) & Pulsed (Hz) (Red Only)
- 100 User Defined Memory Channels
- Display: Full Color TFT Touchscreen Technology
- Power Source: 3.7 VDC Lithium-ion Polymer Battery
- Enclosure: Machined billet aluminum
- · Weight: Less Than 1lb. (.30 kgs) (Device Only)
- · Accessories: Power Cord, Wireless Charging Base, Safety Glasses
- Compliant to: ISO 13485 Medical Device Quality, IEC 60601-1,
 IEC 60601-1-2, IEC 60825-1, CB Certified, CE Mark, CMDCAS
- Laser Class 2 / Device Class II (USA); 2a (EU)

ORDER # EVRL



The Base Station is a desk top unit with three (3) independent handheld laser devices including (1) EVRL, (1) XLR8 laser & (1) GVL laser. This also includes a wireless charging station and the ability to program all of the lasers individually. Physicians are able to use innovative laser therapy in 3 locations at once. Fully impact the ETC with red, green & violet.

- + Laser configuration can be customized to fit physician's needs
- + Stimulate ALL complexes to produce ATP

Payments as low as \$778 per month.

*Price may vary, does does not include tax & shipping.

Specifications

- Configuration: (1) Handheld Devices with Dual 640nm/7.5mW Output Loser Diodes,

 (1) Handheld Device with (1) 640nm/7.5mW Laser Diode and (1) 405nm/7.5mW Laser Diode and

 (1) Handheld Device with (1) 405nm/7.5mW Laser Diode and (1) 520nm/7.5mW loser Diode.
- Wavelengths: 640nm/405nm/520nm
- Modulation: Constant Wave (CW) & Variable Hz
- Up to 100 Programmable Memory Channels
- Base Power Source: Input 100-240 VAC ~ 47-63 Hz/0.5A Max; Output +15 VDC/1.2A max
- Handheld Device Power Source: 3.7 VDC Rechargeable Lithium-ion Polymer Battery
- Enclosure: Machined Billet Aluminum
- Weight: Base Unit with Handheld Laser Devices 2.35 lbs. (1.07kgs.);

Handheld Lasers less than 1lbs. (.30 kgs.) Each

- · Accessories Included: Power Supply & Laser Safety Glasses
- Compliant to: ISO 13485 Medical Device Quality, IEC 60825-1, IEC 60601-1 Safety,
 IEC 60601-1-2 EMC. CB Certified. CE Mark. CMDCAS
- · Laser Class: 2 Device Class II (USA): 2a (EU)

ORDER # BST



THE MOST ADVANCED LASER SCANNERS

IN THE WORLD



The FX 635 patented laser scanner provides physicians with a true self-operating procedure (press start and walk away).

The FX 635 offers the industry's most marketable procedure due to it's wide array of FDA Clearances including plantar fasciitis, chronic low back pain & overall musculoskeletal pain.

- + Touchless & Unattended Technology
- + Highest ROI

*Ask About Pricing.



Specifications

- Configuration: (3) Class 2 17.25mW Line Generating Diodes
- · Wavelength: 640nm
- Modulation: Variable
- Weight: 82lbs (37 kg)
- Height: 70in (177.8 cm) (Average Adjustable)
- · Two Independent Adjustable Arms For Desired Laser Concentration
- . Display: Full Color Touch Screen Control
- Power Source: 100-240VAC, 50-60Hz, 1.5 A 0.5A
- . Chassis: Powder Coated Aircraft Aluminum
- · Housing & Covers: Non-Allergenic Material, Spray Finished
- · Accessories: 2-Keys, Power Cord, Laser Safety Glasses,
- Compliant to: ISO 13485 Medical Device Quality, IEC 60825-1 Laser Safety, IEC 60601-1-2 EMC, IEC 60601-1 Safety, CE Mark, CB Certified
- FDA Laser Class 2 / FDA Device Class II / EU Device Class IIa, Laser Class II

ORDER #FX635



The FX 405 Laser scanner offers all of the same benefits that the FX 635 does, with the advantage of adding violet laser for versatility in treatments.

- + Touchless & Unattended Technology
- + Most Versatile Laser Scanner



Specifications

- Configuration: (3) Class 2, 17.25mW & (1) Class 2, 23mW
 Line Generating Diodes
- Wavelength: 640nm & 405nm
- Modulation: Variable
- Weight: 82lbs (37 kg)
- Height: 70in (177.8 cm) (Average Adjustable)
- Two Independent Adjustable Arms For Desired Laser Concentration
- · Display: Full Color Touch Screen Control
- Power Source: 100-240VAC 50-60Hz, 1.5A 0.5A
- Chassis: Powder Coated Aircraft Aluminum
- · Housing & Covers: Non-Allergenic Material, Spray Finished
- · Accessories: 2-Keys, Power Cord, Laser Safety Glasses,
- Compliant to: ISO 13485 Medical Device Quality, IEC 60825-1 Laser Safety, IEC 60601-1-2 EMC, IEC 60601-1 Safety, CE Mark, CB Certified
- FDA Laser Class 2/FDA Device Class II/EU Device Class IIa, Laser Class II

*Ask About Pricing.

ORDER #FX405



Erchonia Pain Market Clearances

Erchonia complies with the highest clinical testing. All Erchonia level (1) clinical trials have gone through the FDA pre-IDE process, IRB approval, and are based on pilot research to ensure customers that the laser they are purchasing has been proven safe and effective by the FDA. 90% of all medical devices are substantially equivalent with no clinical research, of the 10% that are, only few submit blinded and controlled studies.

United States Food and Drug Administration

- 2002 Chronic Neck and Shoulder Pain
- 2004 Post-Surgical Pain after Liposuction
- 2008 Post-Surgical Pain after Breast Augmentation
- 2014 Chronic Plantar Fasciitis Pain
- 2018 Chronic Low Back Pain
- 2019 Chronic Neck and Shoulder Pain using Red and Violet Laser
- 2019 Overall Nociceptive Musculoskeletal Pain
- 2021 Overall Post-operative Pain
- 2022 Chronic Neck and Shoulder Pain with green & violet

Scan QR code to view all Erchonia FDA Clearances



Scan to visit site.





Erchonia's Zerona Z6 is a full body fat loss treatment that allows clients to target areas of stubborn fat, and is the first laser specifically designed for body contouring. The Zerona Z6 is FDA Market-Cleared, non-invasive, and clinically tested. Applied externally, the laser targets excess fat by emulsifying fatty tissue through the use of cold laser technology developed by Erchonia. It provides an alternative fat loss treatment without the adverse side effects associated with surgical and other weight loss procedures like liposuction, cryolipolysis and body wraps.

ZERONA-Z6 ADVANTAGE:

No Bruising, No Swelling, No Freezing, No Downtime Unattended Treatments Results in as Little as 2 Weeks

*Ask About Pricing.

Specifications

- Configuration: 6 Line Generated Class 2 Laser Diode Modules
- Wavelength: 640nm
- . Modulation: Constant Wave (CW)
- · Display: Full Color TFT Touch Screen Control Center
- Power Source: 100-240VAC 50-60Hz
- Housing: Black Carbon Fiber Finish Thermoformed from Non-Allergen Material
- Weight: 70lbs. (31.76 kg)
- · Accessories: 2-Keys, Laser Safety Glasses
- Compliant to Quality / ISO 13485 Medical Device / ISO 14971 Risk
 Mangement / IEC60825-1 Laser Safety, IEC 60601-1 Safety, IEC 60601-1-2 EMC
- FDA Laser Class 2 / FDA Device Class II

ORDER # ZERONA

FDA Clinical Trials

FDA 510(k) Number: K130741

Indication for use: Relief of minor chronic neck and shoulder pain.

Results: Of the patients who received Erchonia laser treatment, 65.1% met individual success criteria in improvement of pain, while only 11.6% of the placebo subjects (LED's). The overall study success criteria, defined as at least 30% improvement following treatment.

FDA 510(k) Number: K041139

Indication for use: Adjunct to liposuction procedures of the thighs, hips and stomach for reduction of pain associated with the recovery process.

Results: Of the patients who received Erchonia laser treatment, 75% met their major success criteria compared with 32% of the placebo-group patients who received "LED" treatment.

FDA 510(k) Number: K072206

Indication for use: Reduction in post-surgery pain at 24 hours after surgery following bilateral breast augmentation surgery.

Results: Of the patients who received Erchonia laser treatment, 74% met their major success criteria compared with 37% of the placebo-group patients who received "LED" treatment.

FDA 510(k) Number: K190572

Indication for use: The Erchonia FX 635 Laser is indicated for providing relief of nociceptive musculoskeletal pain.

Background: Based on Erchonia's collective clinical performance of over 200 subjects on various musculoskeletal pain conditions, the subjects that met the overall study success was 66.5%, compared to just 17.2% for the sham (LED) group. The mean reduction in the VAS pain scale for the Erchonia laser groups was 50%.

FDA 510(k) Number: K132940

Indication for use: Reducing chronic heel pain arising from plantar fasciitis. **Results:** The patients who received Erchonia laser treatment demonstrated a mean improvement in heel pain on the VAS score of 29.6, compared to with the placebo subjects (LED treatment), mean improvement of just 5.4, a statistically significant difference between groups. In addition, patients which were administered Erchonia Laser completed 12 months of follow-up and demonstrated a continued improvement in heel pain VAS of 67.8 baseline down to 6.9, with no additional laser treatments applied.

FDA 510(k) Number: K180197

Indication for use: Relief of minor chronic low back pain of musculoskeletal origin.

Results: 72.4% of subjects who received the active procedures with the Erchonia®

FX 635 attained a 30% or greater decrease in low back pain VAS rating from baseline to endpoint compared with only 27.6% of subjects who received the LED "placebo" procedures, a statistically significant difference p<0.005. The secondary measure of change on the Oswestry Disability Index (ODI) found the 12.27% mean decrease from study baseline to endpoint for test group subjects to be about two and a half times greater than the relative 5.18% mean decrease for placebo group.

FDA 510(k) Number: K191257

Indication for use: The Erchonia EVRL, red and violet diode, for providing temporary relief of minor chronic neck and shoulder pain of musculoskeletal origin.

Results: Among subjects treated with the red and violet lasers, mean VAS neck and shoulder pain scores decreased from 65.0 to 35.2 (p<0.0001). Most subjects in the study (75%) achieved ≥30% decrease in VAS scores. Subjects experienced a mean 29.07% improvement in neck and shoulder ROM.

Return On Investment

Retail Price	Average number of patients treated per day	Treatments Per Week (Based on 4 day week)	Charge Per Treatment (National Average)	Estimated Monthly Financing Cost	Revenue Per Month	Annual Revenue	1st Year Profit (Cost of device deducted)
FX 635 \$39,900	5	20	\$100	\$780	\$8,000	\$96,000	\$56,100
FX 405 \$44,900	5	20	\$100	\$878	\$8,000	\$96,000	\$51,100
XLR8 \$9,900	5	20	\$30	\$194	\$2,400	\$28,800	\$18,900
EVRL \$15,900	5	20	\$40	\$311	\$3,200	\$38,400	\$22,500
GVL \$19,900	5	20	\$50	\$410	\$4,000	\$48,000	\$28,100
BST *(3 Lasers) \$37,900	15	60	\$40	\$778	\$9,600	\$115,200	\$77,300
Zerona \$59,900	5 Per month		\$1600	\$1150	\$8,000	\$96,000	\$36,100



Whatever you do, do it well.

Do it so well that when you do it they will want to come back and see you do it again and they will want to bring others and show them how well you do what you do. - Walt Disney

QUALITY **NOT** COMPROMISE

















PROYEN NON-INVASIVE DRUG-FREE



Erchonia Corp.
112 Southchase Blvd.
Fountain Inn, SC
(888) 242-0571

